An orally administered antiviral candidate blocked both direct-contact and airborne spread of a measles-like virus in a ferret transmission study, according to research published in Nature Microbiology on 24 July 2026. The compound, GHP-88310, is a broad-spectrum orthoparamyxovirus polymerase inhibitor developed by researchers at Georgia State University’s Center for Translational Antiviral Research (CTAR) — and the airborne-blocking result is notable because measles is among the most airborne-transmissible pathogens known, and no viral polymerase inhibitor had previously been shown to interrupt that specific transmission route.
What the study found
The paper, titled “Antiviral GHP-88310 blocks contact-mediated and airborne transmission in a ferret model of measles-like disease,” used canine distemper virus (CDV) as the experimental model. CDV is a close relative of measles virus that causes a similar disease course in ferrets and is used as a laboratory surrogate because measles virus itself does not naturally infect the species. Ferrets were housed either in direct contact with infected animals or in adjacent enclosures that shared airflow but no physical contact, then treated with GHP-88310 either before or shortly after exposure.
The drug substantially reduced transmission through both routes. According to coverage of the findings, animals that were already infected before treatment also remained infectious for a shorter period than untreated controls — a property relevant to post-exposure use during an active outbreak, not just prophylaxis.
How the drug works
GHP-88310 targets the viral RNA-dependent RNA polymerase shared across orthoparamyxoviruses, the family that includes measles virus. By inhibiting this enzyme, the compound limits the virus’s ability to replicate efficiently, which in turn appears to reduce both the quantity and infectiousness of virus shed by an infected host — the likely mechanism behind the drop in onward transmission observed in the study. Because the target is a conserved viral enzyme rather than a host protein, the same mechanistic approach may generalize to other members of the same virus family, though that remains to be demonstrated.
Why this matters for outbreak response
The result lands amid a sustained resurgence of measles in multiple countries, driven substantially by gaps in vaccination coverage. Vaccination remains the primary tool for measles prevention and outbreak control, and nothing in this preclinical study changes that. What a transmission-blocking oral antiviral could add, if it eventually clears clinical development, is a second layer of defense: a treatment that could be given to exposed contacts or early-stage cases to curb further spread during an active outbreak, complementing rather than replacing immunization.
That distinction matters for how research administrators and funders should read this kind of result. A ferret transmission study is preclinical, mechanistic, and several stages removed from a licensed therapeutic — the researchers describe the compound as being prepared for further development toward formal clinical testing, not as a treatment ready for use.
Animal-research oversight in translational antiviral work
Studies of this kind — infecting animals with a pathogen surrogate specifically to measure transmission between them — sit at the more tightly scrutinized end of animal research and are reviewed accordingly. In the United States, any vertebrate-animal research conducted with federal funding is subject to institutional oversight by an Institutional Animal Care and Use Committee (IACUC), which reviews the study protocol before work begins for scientific justification, animal welfare safeguards, and application of the 3Rs framework (replacement, reduction, refinement). Using a naturally occurring surrogate virus like CDV rather than measles virus itself is itself a refinement choice that keeps the model at a lower biosafety containment level while still producing a clinically relevant disease course. For a fuller treatment of how this oversight structure works, see CASRAI’s guide to animal research ethics, the 3Rs, and IACUC oversight.
Institution and funding
The research was led by Richard K. Plemper, Regents’ Professor and director of CTAR, with first author Carolin M. Lieber and co-authors Josef D. Wolf, Claire E. Ruckel, and Lauren A. Harrison, all based at the Center for Translational Antiviral Research within Georgia State University’s Institute for Biomedical Sciences in Atlanta. According to the published record, the work was supported by grants from the National Institutes of Health / National Institute of Allergy and Infectious Diseases (NIH/NIAID), AI071002 and AI171403 — consistent with the federal government’s longstanding role in funding early-stage antiviral countermeasure development against outbreak-prone pathogens.
What’s next
The study is preclinical: it demonstrates transmission-blocking in an animal model, not efficacy or safety in humans. The research team has indicated it is preparing GHP-88310 for formal clinical testing. Any path from here to clinical use would still require the standard progression through investigational new drug (IND) filing, Phase 1 safety trials, and further efficacy studies — a multi-year process even for a promising candidate.
Source: Lieber, C.M., Wolf, J.D., Ruckel, C.E., Harrison, L.A. & Plemper, R.K. “Antiviral GHP-88310 blocks contact-mediated and airborne transmission in a ferret model of measles-like disease.” Nature Microbiology (2026). DOI: 10.1038/s41564-026-02419-y.
